- Home
- RBNE vs BRTX Comparison
RBNE vs BRTX Comparison
Compare RBNE & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | BRTX |
|---|---|---|
| Founded | 2024 | 1997 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RBNE | BRTX |
|---|---|---|
| Price | $1.07 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 206.4K | ★ 23.0M |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $0.16 |
| 52 Week High | $20.57 | $2.04 |
Technical Indicators
Market Signals| Indicator | RBNE | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 58.50 |
| Support Level | $0.69 | $0.20 |
| Resistance Level | $1.41 | $1.22 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 20.89 | 41.62 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd is engaged in the ownership and operation of vessels providing seaborne transportation of refined petroleum products and liquefied petroleum gas (LPG). The company operates in two reportable segments: the Tanker segment and the LPG carrier segment.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.